Veterinary Vaccines Market By Vaccine Type (Live-attenuated, Inactivated, Toxoids, Recombinant Subunit, RNA/DNA-based, Vectored-based), By Animal Type (Livestock, Pet Animals), By Disease Type (Viral Diseases, Bacterial Diseases, Parasitic Diseases, Non-Infectious Diseases, Fertility) - Growth, Future Prospects & Competitive Analysis, 2018 – 2026

Industry Outlook

Immunization of livestock has been carried out worldwide for centuries and is also accepted as a cost-effective measure for controlling infections. Until recently, vaccines were either live attenuated or inactivated organisms formulated with an oil-based adjuvant; however, these methods and formulations were not very effective. The introduction of gene delivery systems has rendered the development of novel therapeutic and prophylactic vaccines possible. The identification of vaccine candidates in genomic sequences proved to be a revolutionary approach, where antibodies were assumed to easily access the cell surface. Reverse vaccination makes use of different bioinformatics algorithms for predicting antigen localization and is now successfully applied for immunization against a range of veterinary diseases.

The global veterinary vaccines market is being driven by the increasing prevalence of animal diseases and the increasing demand for companion animals. Vaccination protects millions of animals from diseases and fatalities. As the field of veterinary medicine advances, disease prevention has become a priority. Therefore, one of the best measures for disease prevention is enhancing animal immunity. Vaccination programs for farm animals depend on management systems, farm location, and the nature of the herd or flock. Veterinary vaccines continue to play a major role in protecting animal health and, consequently, ensuring public health and reducing the use of antibiotics in animals. Some prominent veterinary vaccines include the rinderpest and rabies vaccines. Rabies vaccines for domestic and wild animals have nearly eradicated the risk of human rabies. The Global Rinderpest Eradication Program, which involved trade restrictions, surveillance, and vaccination, has led to a significant reduction in incidence, making it the second disease after smallpox to be eradicated worldwide. Prominent examples of new technologies in animal vaccines that are licensed include DNA vaccines, virus-like particle vaccines, and recombinant, modified live virus vaccines. Animal vaccines also make use of novel adjuvants that are not yet incorporated into human use. Furthermore, animal vaccines can also be developed and commercialized more quickly than human vaccines. Furthermore, for animal vaccines to effectively safeguard animal health, they should be widely used and, therefore, affordable. Regulatory processes, therefore, need to ensure product safety and efficacy without increasing licensing and production costs.

Market Synopsis

live-attenuated vaccines to dominate the global market

Live-attenuated vaccines based on genetic mutation are the most dominant segment in the global market. Better long-term immunity, the inclusion of both cellular and humoral immunity, efficacy, and targeting, and ease of administration are the key factors that support the dominance of this segment. However, the fact that live strains are not very effective and require refrigerated storage may restrain the market growth of this segment. Live attenuated vaccines are created in two ways: by combining attenuated animal or human virus strains or by serially passing initially pathogenic viruses or bacteria and selecting less pathogenic strains that may induce protective immunity. These vaccines are believed to augment the immunologic response, similar to the response resulting from a natural infection. The advantage of a live-attenuated vaccine is the replication of organisms and antigen processing that mimics a natural infection, both cell-mediated and humoral. Such conferred immunity may also be long-lasting or even lifelong.

High demand for pets and companion animals, as well as increased healthcare spending in this demographic, will drive market growth.

At present, livestock, particularly porcine breeds, occupy the largest share in the consumption of veterinary vaccines. The increase in global consumption of livestock through meat and dairy products is the prime factor driving the dominance of this segment. As the global population increases, the world faces more mouths to feed with nutritional products, which has urged the food industry to enhance the production of farm animals. The purpose of using vaccines for livestock is to increase productivity and profitability for producers. The use of vaccination for zoonotic diseases in livestock is expected to eliminate or reduce the risk of transmission of these diseases to consumers while also protecting industry animals. The large-scale use of nontherapeutic antibiotics in livestock has resulted in the emergence of antibiotic-resistant bacteria. Such issues have increased the use of vaccines in livestock animals. On the other hand, the growth rate of pet and companion animal vaccines is expected to surpass the overall market benchmark during the forecast period. In companion animal vaccines, canine vaccines hold the most prominent share and will assist in the development of the market through the forecast period. Increased adoption of pet animals in the general population, heightened uptake among disabled patients, and increasing spending on scheduled well-being measures for such animals are the key factors facilitating the swift growth of this segment.

Vaccines for Viral and Bacterial Infections Spearhead the Global Market

At present, there are no broad-spectrum antiviral medications available for veterinary purposes. Therefore, employment of a hygienic environment, limiting exposure, and vaccination are the only methods for the prevention of viral infections in animals. RNA viruses are very variable, and many viral infections occur from viruses with different serotypes. Therefore, several of the currently available viral vaccines are not able to combat infections caused by the prevailing strains. Several conventional inactivated and live-attenuated vaccines are being produced by veterinary health companies and have been on the market for many decades as a part of the routine vaccination protocol. Furthermore, many subunits and rationally designed vaccines are being introduced into the market. Several prophylactic live, attenuated, or inactivated bacterial vaccines are available on the market. For a majority of attenuated bacterial strains, the form of attenuation is unknown, and since there is no proven track record, researchers have done little to characterize the underlying genetics. However, in some cases, the old live strains are not very protective, and perpetual research is being conducted to develop new and improved vaccine strategies against diseases such as paratuberculosis, brucellosis, and bovine tuberculosis.

Because of increased awareness and a favorable business environment, the United States leads the global veterinary vaccines market.

Geographically, North America, particularly the United States, holds the largest revenue share in the global veterinary vaccine market. Enhanced and widespread vaccination programs, increasing adoption of companion animals, and greater awareness are the key factors supporting the dominance of this regional market. Furthermore, acceptance of advanced vaccine products such as DNA and recombinant vaccines is also significantly high in North America. Asia Pacific shall advance at the fastest growth rate during the forecast period from 2018 to 2026. The ownership of companion animals is perpetually growing in the region due to increasing disposable incomes. Livestock farming in Asia-Pacific is also perpetually advancing in terms of animal healthcare and technologies. Countries such as India, China, Brazil, and South Africa will be the fastest-progressing country-level markets.

Periods of History and Forecast

This research report presents the analysis of each considered segment for the period from 2016 to 2026, using 2017 as the base year for estimations. Compounded annual growth rates (CAGRs) for each segment are calculated for the forecast period from 2018 to 2026.

Report Scope by Segments

This report presents a market analysis of veterinary vaccines in terms of qualitative and quantitative information for the forecast period of 2016–2026. The study includes qualitative information such as market analysis for each mentioned segment, market drivers, challenges, and opportunities relevant to the industry. The global veterinary vaccines market is segmented in terms of vaccine types, wound types, disease types, and geography.

The report also presents insights into the competitive landscape prevalent in the global veterinary vaccines market, along with a profile of key companies operating in the industry. Such major market players profiled in this report include Merck Animal Health, Zoetis, Inc., Merial (Boehringer Ingelheim International GmbH), Elanco Animal Health, Bayer Animal Health, Novartis Animal Health, Virbac Group, Ceva Santé Animale S.A., and Biovac.

Key questions are answered in this report.

  • What is the market size and forecast for the period from 2016 to 2026?
  • What is the compounded annual growth rate of the global veterinary vaccine market?
  • How does the livestock animal segment hold dominance in the global market?
  • What is the market potential for DNA and recombinant vaccines?
  • What are the drivers, challenges, and opportunities relevant to the industry?
  • How will the Asia-Pacific region progress on the global front?
  • What is the competitive landscape in the global veterinary vaccines market, and which companies hold key positions in the global market?
  • What is the situation of emerging markets in the Middle East, Africa, and Latin America through the forecast period?

 Frequently Asked Questions:

The market for Veterinary Vaccines is expected to reach US$ XX Mn in 2026.

The Veterinary Vaccines market is expected to see significant CAGR growth over the coming years,at XX%.

The report is forecasted from 2018-2026.

The base year of this report is 2017

Merck Animal Health,Zoetis Inc., Merial(Boehringer Ingelheim International GmbH),Elanco Animal Health,Bayer Animal Health are some of the major players in the global market.

Choose License Type
Trusted By
Published Date:  Sep 2018
Category:  Pharmaceuticals
Report ID:   59349
Report Format:   PDF
Pages:   120
Rating:    4.4 (56)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
24/7 Research Support